Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis

The Concept of reusing existing drugs for new targets is gaining momentum in recent years because of cost-effectiveness as safety and toxicology data are already available. Therefore, it is of interest to re-profile known drugs against the Pim-1 kinase target using molecular docking analysis. Result...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrouchi, Housna, Lakhlili, Wiame, Ibrahimi, Azeddine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677905/
https://www.ncbi.nlm.nih.gov/pubmed/31435157
http://dx.doi.org/10.6026/97320630015116
_version_ 1783440978800017408
author Arrouchi, Housna
Lakhlili, Wiame
Ibrahimi, Azeddine
author_facet Arrouchi, Housna
Lakhlili, Wiame
Ibrahimi, Azeddine
author_sort Arrouchi, Housna
collection PubMed
description The Concept of reusing existing drugs for new targets is gaining momentum in recent years because of cost-effectiveness as safety and toxicology data are already available. Therefore, it is of interest to re-profile known drugs against the Pim-1 kinase target using molecular docking analysis. Results show that known drugs such as nilotinib, vemurafenib, Idelalisib, and other small kinases inhibitors have high binding ability with Pim-1 kinase for consideration as potential inhibitors.
format Online
Article
Text
id pubmed-6677905
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Biomedical Informatics
record_format MEDLINE/PubMed
spelling pubmed-66779052019-08-21 Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis Arrouchi, Housna Lakhlili, Wiame Ibrahimi, Azeddine Bioinformation Research Article The Concept of reusing existing drugs for new targets is gaining momentum in recent years because of cost-effectiveness as safety and toxicology data are already available. Therefore, it is of interest to re-profile known drugs against the Pim-1 kinase target using molecular docking analysis. Results show that known drugs such as nilotinib, vemurafenib, Idelalisib, and other small kinases inhibitors have high binding ability with Pim-1 kinase for consideration as potential inhibitors. Biomedical Informatics 2019-02-28 /pmc/articles/PMC6677905/ /pubmed/31435157 http://dx.doi.org/10.6026/97320630015116 Text en © 2019 Biomedical Informatics http://creativecommons.org/licenses/by/3.0/ This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
spellingShingle Research Article
Arrouchi, Housna
Lakhlili, Wiame
Ibrahimi, Azeddine
Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title_full Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title_fullStr Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title_full_unstemmed Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title_short Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
title_sort re-positioning of known drugs for pim-1 kinase target using molecular docking analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677905/
https://www.ncbi.nlm.nih.gov/pubmed/31435157
http://dx.doi.org/10.6026/97320630015116
work_keys_str_mv AT arrouchihousna repositioningofknowndrugsforpim1kinasetargetusingmoleculardockinganalysis
AT lakhliliwiame repositioningofknowndrugsforpim1kinasetargetusingmoleculardockinganalysis
AT ibrahimiazeddine repositioningofknowndrugsforpim1kinasetargetusingmoleculardockinganalysis

Ejemplares similares